Allergan PLC (AGN)

Common-Size Income Statement
Quarterly Data

Beginner level

Allergan PLC, common-size consolidated income statement (quarterly data)

	3 months ended	Sep 30, 2019		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Net revenues
	Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
	Gross profit
	Research and development
	Selling and marketing
	General and administrative
	Amortization
	Goodwill impairments
	In-process research and development impairments
	Loss on assets held for sale
	Asset sales and impairments, net
	Operating income (loss)
	Interest income
	Interest expense
	Other income (expense), net
	Other income (expense), net
	Income (loss) before income taxes and noncontrolling interest
	(Provision) benefit for income taxes
	Net income (loss) from continuing operations, net of tax
	Income (loss) from discontinued operations, net of tax
	Net income (loss)
	(Income) loss attributable to noncontrolling interest
	Net income (loss) attributable to shareholders
	Dividends on preferred shares
	Net income (loss) attributable to ordinary shareholders

Income statement item	Description	The company
Operating income (loss)	The net result for the period of deducting operating expenses from operating revenues.	Allergan PLC’s operating income (loss) as a percentage of net revenues increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Income (loss) before income taxes and noncontrolling interest	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Allergan PLC’s income (loss) before income taxes and noncontrolling interest as a percentage of net revenues increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Net income (loss) attributable to shareholders	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Allergan PLC’s net income (loss) attributable to shareholders as a percentage of net revenues increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

	Allergan PLC	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality